文献速递核素与放射性配体治疗放射性药物与辐射防护

美国国家癌症研究所对靶向α发射体治疗的支持

National Cancer Institute support for targeted alpha-emitter therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-08-11

本文综述了美国国家癌症研究所(NCI)通过研讨会、兴趣小组、院外基金、院内研究等多种方式支持放射性药物治疗(RPT)及靶向α发射体治疗(TAT)的举措。NCI通过同行评审研究项目、小企业创新研究、癌症治疗评估项目等资助RPT研究,并持续开展临床前TAT研究,旨在推动高质量证据生成以促进多学科治疗临床应用。

要点

  • NCI通过研讨会和兴趣小组促进RPT及剂量学的社区交流与严谨研究
  • NCI资助RPT研究包括院外研究项目、小企业创新研究及院内临床前研究
  • NCI癌症治疗评估项目的放射性药物开发计划支持RPT临床试验中的影像QA与剂量学

核心结论

  • 鉴于RPT的巨大潜力,NCI目标是继续鼓励其发展以生成将多学科治疗带给患者所需的高质量证据。

研究设计与样本

  • 本文为综述,回顾NCI通过研讨会、兴趣小组、院外项目资助和院内研究对RPT及TAT的支持。

主要发现

  • NCI共同组织了RPT和RPT剂量学研讨会并组织兴趣小组以鼓励社区和促进严谨的临床前与临床研究。
  • NCI通过同行评审的研究与项目 grants 和小企业创新研究发展中心资助RPT研究,部分项目已进入临床试验。
  • NCI癌症治疗评估项目的放射性药物开发计划支持NCI资助的临床试验中的RPT,包括影像QA和剂量学程序。
  • NCI院内项目正在开展临床前TAT研究,基于可追溯至1980年代的基础工作,并利用NIH临床中心的独特基础设施进行转化研究。

临床怎么用

  • 核医学科智能体医生可关注NCI支持的RPT临床试验资源、影像QA与剂量学标准,以促进多学科治疗规范开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped renewed interest in the modality. METHODS: This article reviews National Cancer Institute (NCI)'s support of RPT through communication via workshops and interest groups, through funding extramural programs in academia and small business, and through intramural research, including preclinical and clinical studies. RESULTS: NCI has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer-reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials. The NCI Cancer Therapy Evaluation Program (CTEP)'s Radiopharmaceutical Development Initiative supports RPT in NCI-funded clinical trials, including Imaging and Radiation Oncology Core (IROC) expertise in imaging QA and dosimetry procedures. Preclinical targeted a-emitter therapy (TAT) research at the NCI's intramural program is ongoing, building on foundational work dating back to the 1980s. Ongoing "bench-to-bedside" efforts leverage the unique infrastructure of the National Institutes of Health's (NIH) Clinical Center. CONCLUSION: Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high-quality evidence needed to bring this multidisciplinary treatment to patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hong JA, Brechbiel M, Buchsbaum J, et al. National Cancer Institute support for targeted alpha-emitter therapy. Eur J Nucl Med Mol Imaging. 2021. PMID: 34378064. doi:10.1007/s00259-021-05503-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。